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ABSTRACT 
 
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor, which plays a 
pivotal part in the development of the central nervous system. Aberrant expression of 
full-length ALK occurs in neuroblastoma and chromosomal translocation or inversion of 
the ALK gene can generate novel fusion-ALK proteins that possess constitutive kinase 
activity and contribute to oncogenic processes. One of the well-studied fusion proteins is 
nucleophosmin (NPM-ALK), which draws a lot of attention for medicinal chemists to 
design small molecules as kinase inhibitors for this target. In this dissertation, [1, 2, 4]-
Dihydrotriazine dimers as competitors of the lead compound NVP-TAE684 targeting 
NPM-ALK have been designed and synthesized. Molecular modelling studies show that 
those dihydrotriazine dimers have a great potential to be better kinase inhibitors.  
Chapter two describes imaging in the drug discovery and development arena. One 
of important imaging techniques is positron emission tomography (PET).  PET is a 
radionuclide based molecular imaging technique, which can be used for early detection, 
characterization, “real time” monitoring of diseases, and investigation of the efficacy of 
drugs. Fluorine-18 (18F) based molecular probes for PET imaging still remain big 
challenging to prepare but have gained increased interest by radiochemists in the past two 
decades. In this study, a novel approach to introduce fluorine into a molecular probe has 
been discovered based on boron chemistry. A few novel fluorine capture reagents have 
been synthesized and described in this Chapter. 
1 
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CHAPTER ONE: 
SYNTHESIS OF [1, 2, 4]-DIHYDROTRIAZINE NUCLEUS AS A NEW KINASE 
INHIBITOR 
 
1.1 Introduction 
Anaplastic lymphoma kinase (ALK)[1,2] is a receptor tyrosine kinase of the insulin 
receptor superfamily, as shown in Figure 1.1. It is believed that it plays a pivotal part in 
the development of the central nervous system. Aberrant expression of full-length ALK 
occurs in neuroblastoma and chromosomal translocation or inversion of the ALK gene 
can generate novel fusion-ALK proteins that possess constitutive kinase activity and 
contribute to oncogenic processes[3, 4]. One of the well-studied fusion proteins is
nucleophosmin (NPM-ALK), which has constitutive tyrosine kinase activity and a strong 
oncogenic potential and is responsible for neoplastic transformation5.  It is believed that 
overexpression and activation of NPM-ALK fusion protein can drive the survival and 
proliferation of anaplastic large cell lymphomas (ALCLs)6. The signal transduction 
pathway activated by NPM-ALK is shown in Figure7 1.2. 
There are a lot of ALK inhibitors that have been reported, the most important 
ligand is NVP-TAE684, which is a highly potent and selective small molecule inhibitor 
targeting NPM-ALK protein with an IC50 value at 2~10 nM in vitro activity[5, 6, 8].   
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dihydrotriazine scaffold. X-ray crystal structures of ALK enzymes, PDB ID: 2XB7, were 
prepared, optimized, and refined using Schrodinger’s Protein Preparation Wizard at a 
neutral pH. The ligands to be docked were prepared using Schrodinger’s Ligprep in 
which the ionization states were generated within a pH range of 5-9 using Epik. Grids 
were prepared using the Glide Grid Generation. Ligands were docked with SP (standard 
precision) and XP (extra precision) using default settings. 
The docking scores of the XP docking of the ligands with the greatest affinity 
ranged from -6.48kcal/mol to -9.484 kcal/mol. (As shown in Table 1.1) 
 
Table 1.1 XP Ligand Dockings to 2XB7 
Protein: 2XB7 
Water in binding site: Yes 
Ligand R1 R2 Docking Score 
Known ligand NVP-TAE684     -8.575 
Experimental Ligands 
1.5a Methyl Methyl -8.12 
1.5b Methyl Isobutyl -8.125 
1.5c Methyl Benzyl -8.941 
1.5d Methyl 3-Methylindole -7.746 
1.5e Benzyl Methyl -9.029 
1.5f Benzyl Isobutyl -9.094 
1.5g Benzyl Benzyl -8.234 
1.5h Benzyl 3-Methylindole -8.664 
1.5i Isobutyl Methyl -6.48 
1.5j Isobutyl Isobutyl -8.495 
1.5k Isobutyl Benzyl -8.774 
1.5l Isobutyl 3-Methylindole -9.484 
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(a) KOH, DMF, Isobutyl bromide, 0-25 oC, 53% (b) n-BuLi, LiBr, CuBr, -45 oC, then CS2,
followed by CH3I, 64-70% (c) Amino acid methyl ester hydrochloride, TEA, DCM, 20-25 oC, 63-95%
(d) H2NNH2.H2O, 1,4-dioxane, ref lux, 47-78%
b c
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Scheme 1.1 Synthesis of 1, 2, 4-dihydrotriazine dimer. 
 
 
The preparation of thio-ester 1.3 is listed in Table 1.2, and the following [1, 2, 4]-
dihydrotriazine precursor 1.4 is listed in Table 1.3 and final library compound of [1, 2, 
4]-dihydrotriazine dimer was shown in Table 1.5. 
        
Table 1.2 Preparation of thio-ester 1.3 
  R1 Percent yield 
1.3a Methyl 70% 
1.3b Benzyl 69% 
1.3c Isobutyl 64% 
     
        
  
10 
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Table 1.3 Preparation of [1, 2, 4]-dihydrotriazine precursor 1.4 
  R1 R2 Percent yield 
1.4a Methyl Methyl 84% 
1.4b Methyl Isobutyl 71% 
1.4c Methyl Benzyl 85% 
1.4d Methyl 3-Methylindole 69% 
1.4e Benzyl Methyl 94% 
1.4f Benzyl Isobutyl 63% 
1.4g Benzyl Benzyl 88% 
1.4h Benzyl 3-Methylindole 72% 
1.4i Isobutyl Methyl 85% 
1.4j Isobutyl Isobutyl 81% 
1.4k Isobutyl Benzyl 95% 
1.4l Isobutyl 3-Methylindole 70% 
 
Table 1.4 Library of the synthesized [1, 2, 4]-dihydrotriazine dimer 1.5 
  R1 R2 Percent yield 
1.5a Methyl Methyl 49% 
1.5b Methyl Isobutyl 79% 
1.5c Methyl Benzyl 57% 
1.5d Methyl 3-Methylindole 76% 
1.5e Benzyl Methyl 58% 
1.5f Benzyl Isobutyl 47% 
1.5g Benzyl Benzyl 52% 
1.5h Benzyl 3-Methylindole 68% 
1.5i Isobutyl Methyl 67% 
1.5j Isobutyl Isobutyl 68% 
1.5k Isobutyl Benzyl 78% 
1.5l Isobutyl 3-Methylindole 72% 
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1.3 Conclusion and Future Plan 
From the docking studies, a few experimental ligands are better than the known 
ligand (NVP-TAE684), especially ligand 1.5L has highest docking score, indicating it 
may be the potential candidate as inhibitor of anaplastic lymphoma kinase (ALK)-driven 
cancers. 
In summary, [1, 2, 4]-dihydrotriazine scaffold has been successfully designed and 
library compound has been built up against NPM-ALK. Totally twenty-eight compounds 
have been made and twelve [1, 2, 4]-dihydrotriazine dimers have been successfully 
synthesized, the overall yield is up to 51% in three step synthesize. All the [1, 2, 4]-
dihydrotriazine dimers will be screened and tested against NPM-ALK enzyme as well as 
other ALK-driven enzyme assay for potential anticancer activity in the future study. 
 
1.4 Experimental Section 
1.4.1 Materials and Methods 
Organic and inorganic reagents (ACS grade) and solvents were obtained from 
commercial sources and used without further purification, unless otherwise noted. 
Moisture and air-sensitive reactions were carried out under an inert atmosphere of 
nitrogen. Thin layer chromatography (TLC) was performed on glass plates pre-coated 
with 0.25mm thickness of silica gel (60F-254) with fluorescent indicator. Column 
chromatographic purification was performed using silica gel 60 Å, (# 70-230 mesh). All 
1H NMR and 13C NMR spectra were recorded on Varian INOVA 400 MHz or Bruker 
250 MHz spectrometer at 25 oC in chloroform-d (CDCl3) or dimethyl sulfoxide-d6 
(DMSO-d6), unless otherwise specified. Chemical shifts are reported in parts per million 
12 

(ppm) relative to internal standard tetramethylsilane (TMS). Multiplicity is expressed as 
(s = singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, or m = multiplet) and 
the values of coupling constants ( J ) are given in Hertz (Hz). High Resolution Mass 
Spectrometry (HRMS) spectra were carried out on an Agilent 1100 Series in the ESI-
TOF mode.

1.4.2 Experimental Procedures 
1-Isobutyl-1H-imidazole (1.2c)12 
 
To a solution of imidazole 1.1 (3.404 g, 50.0 mmol) in dimethylformamide 
(DMF) (100 mL) was added potassium hydroxide (KOH) (4.20 g, 75.0 mmol) at room 
temperature under nitrogen. The reaction mixture was stirred at room temperature for 5 
hrs, then cooled down to 0 oC with ice bath. Isobutyl bromide (6.85 g, 50.0 mmol) was 
then added dropwise, the resulting mixture was allowed to warm up to room temperature 
and stirred overnight. The reaction mixture was then concentrated in vacuum and the 
residue was partitioned between dichloromethane (DCM) (100 mL) and water (50 mL). 
The aqueous layer was extracted with DCM (2* 50 mL), and organic layer was 
combined, dried over anhydrous sodium sulfate (Na2SO4), filtered and concentrated to 
give a light yellow oil as crude compound. The crude oil was purified by vacuum 
distillation to afford compound 1.2c as a colorless oil (3.32 g, 53%). 1HNMR (400MHz, 
CDCl3)  ppm = 7.32 (s, 1 H), 6.92 (s, 1 H), 6.77 (s, 1 H), 3.61 (d, J=7.0 Hz, 2 H), 1.74 - 
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2.07 (m, 1 H), 0.79 (d, J=6.6 Hz, 6 H). 13CNMR (101MHz, CDCl3)  ppm = 137.3, 
129.0, 119.1, 54.4, 30.0, 19.7. HRMS-ESI (m/z): [M+H]+ calcd. for C7H13N2: 125.1073, 
found, 125.1078.  
 
Methyl 1-methyl-1H-imidazole-2-carbodithioate (1.3a)13 
 
General Procedure A. To a solution of 10.0 mmol of n-butyllithium in hexanes 
was added 20 mL of THF, cooled down to below -40 oC under nitrogen. 1-
Methylimidazole 1.2a (821.0 mg, 10.0 mmol) in 5 mL of tetrahydrofuran (THF) was then 
added dropwise during 5 mins at -55 oC. After an additional 10 mins (at the above 
temperature mentioned) stirring, a solution of copper (I) bromide (261.08 mg, 1.82 mmol) 
and anhydrous lithium bromide (316.1 mg, 3.64 mmol) in 30 mL of THF was added 
dropwise during 10mins, followed by carbon disulfide (761.4 mg, 10.0 mmol) in 5 mL of 
THF at the same temperature. Methyl iodide (1.562 g, 11.0 mmol) was then added in one 
portion. The reaction temperature was then allowed to warm to +15 oC. Once the reaction 
was completed, a solution of 1.8 g of potassium cyanide in 40 mL of water was added to 
quench this reaction. The reaction solution was then separated, the aqueous layer was 
extracted with ethyl acetate, and organic layer was combined, dried over anhydrous 
magnesium sulfate (MgSO4), filtered and concentrated in vacuum to obtain a red-brown 
oil as crude compound.  The resulting crude was purified by flash column 
chromatography (silica gel, EtOAc: Hexanes = 1:4 as eluent) to afford compound 1.3a as 
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a bright-red solid (1.21 g, 70%). 1HNMR (400MHz, CDCl3)  ppm = 7.05 (s, 1 H), 7.03 
(s, 1 H), 3.96 (s, 3 H), 2.57 (s, 3 H). 13CNMR (101MHz, CDCl3)  ppm = 211.8, 147.5, 
128.4, 128.2, 37.9, 18.9. HRMS-ESI (m/z): [M+H]+ calcd. for C6H9N2S2: 173.0202, 
found, 173.0209.  
 
Methyl 1-benzyl-1H-imidazole-2-carbodithioate (1.3b) 
 
Compound 1.3b was prepared from 1-benzylimidazole 1.2b according to general 
procedure A to afford 1.3b as a bright-red oil (69% yield). 1HNMR (400MHz, CDCl3)  
ppm = 7.21 - 7.34 (m, 3 H), 7.17 (s, 1 H), 7.01 - 7.11 (m, 3 H), 5.81 (s, 2 H), 2.62 (s, 3 
H). 13CNMR (101MHz, CDCl3)  ppm = 212.3, 147.1, 136.0, 128.8, 128.5, 127.9, 127.2, 
52.0, 19.0. HRMS-ESI (m/z): [M+H]+ calcd. for C12H13N2S2: 249.0515, found, 
249.0527.  

Methyl 1-isobutyl-1H-imidazole-2-carbodithioate (1.3c) 
 
Compound 1.3c was prepared from 1-isobutylimidazole 1.2c according to general 
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procedure A to afford 1.3c as a bright-red oil (64% yield). 1HNMR (400MHz, CDCl3)  
ppm = 7.10 (d, 2 H), 4.33 (d, J=7.4 Hz, 2 H), 2.63 (s, 3 H), 2.01 - 2.18 (m, 1 H), 0.86 (d, 
J=6.6 Hz, 6 H). 13CNMR (101MHz, CDCl3)  ppm = 212.7, 147.0, 127.9, 127.8, 55.9, 
29.5, 19.6, 19.0. HRMS-ESI (m/z): [M+H]+ calcd. for C9H15N2S2: 215.0671, found, 
215.0678.  
 
Methyl 2-(1-methyl-1H-imidazole-2-carbothioamido)propanoate (1.4a)14 
 
General Procedure B. To a solution of alanine methyl ester hydrochloride (844.5 
mg, 6.05 mmol) in 40 mL of anhydrous CH2Cl2 at room temperature (RT) under nitrogen 
was added triethylamine (TEA) (0.914 mL, 6.6 mmol), followed by compound 1.3a 
(947.5 mg, 5.5 mmol).  
The reaction mixture was then stirred for 15 hrs at room temperature, and the 
solvent was evaporated. The resulting residue was purified by flash column 
chromatography (silica gel, EtOAc: Hexanes = 1:4 as eluent) to afford compound 1.4a as 
a light yellow solid (1.05 g, 84%). 1HNMR (400MHz, CDCl3)  ppm = 9.49 - 9.87 (m, 1 
H), 7.00 (d, J=7.8 Hz, 2 H), 5.15 (t, J=7.2 Hz, 1 H), 4.15 (s, 3 H), 3.76 (s, 3 H), 1.58 (d, 3 
H). 13CNMR (101MHz, CDCl3)  ppm = 182.0, 172.1, 142.2, 127.5, 126.3, 52.5, 52.4, 
38.0, 17.1. HRMS-ESI (m/z): [M+H]+ calcd. for C9H14N3O2S: 228.0801, found, 
228.081. 
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Methyl 4-methyl-2-(1-methyl-1H-imidazole-2-carbothioamido)pentanoate 
(1.4b) 
 
Compound 1.4b was prepared from compound 1.3a and leucine methyl ester 
hydrochloride according to general procedure B to afford 1.4b as a light yellow solid (71% 
yield). 1HNMR (400MHz, CDCl3)  ppm = 9.59 (d, J=5.9 Hz, 1 H), 7.01 (d, J=8.6 Hz, 2 
H), 5.13 - 5.25 (m, 1 H), 4.17 (s, 3 H), 3.74 (s, 3 H), 1.81 - 1.89 (m, 2 H), 1.69 - 1.81 (m, 
1 H), 0.96 (dd, 6 H). 13CNMR (101MHz, CDCl3)  ppm = 182.4, 171.9, 142.0, 127.5, 
126.2, 55.3, 52.3, 40.6, 38.1, 25.0, 22.7, 22.1. HRMS-ESI (m/z): [M+H]+ calcd. for 
C12H20N3O2S: 270.1271, found, 270.1282.
 
Methyl 2-(1-methyl-1H-imidazole-2-carbothioamido)-3-phenylpropanoate 
(1.4c) 
 
Compound 1.4c was prepared from compound 1.3a and phenylalanine methyl 
ester hydrochloride according to general procedure B to afford 1.4c as a light yellow oil 
(85% yield). 1HNMR (400MHz, CDCl3)  ppm = 9.78 (d, J=5.9 Hz, 1 H), 7.21 (m, 5 H), 
7.00 (d, J=10.9 Hz, 2 H), 5.39 - 5.51 (m, 1 H), 4.15 (s, 3 H), 3.70 (s, 3 H), 3.32 (t, J=6.8 
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Hz, 2 H). 13CNMR (101MHz, CDCl3)  ppm = 181.9, 170.7, 142.0, 135.7, 129.2, 128.6, 
127.5, 127.1, 126.2, 57.8, 52.3, 38.1, 37.1. HRMS-ESI (m/z): [M+H]+ calcd. for 
C15H18N3O2S: 304.1114, found, 304.1119.
 
Methyl 3-(1H-indol-3-yl)-2-(1-methyl-1H-imidazole-2-
carbothioamido)propanoate (1.4d) 
N
N
H
N
O
O
S
NH
 
Compound 1.4d was prepared from compound 1.3a and tryptophan methyl ester 
hydrochloride according to general procedure B to afford 1.4d as yellow foamy powder 
(69% yield). 1HNMR (400MHz, CDCl3)  ppm = 9.75 (d, 1 H), 8.31 (br. s., 1 H), 7.57 (d, 
J=7.8 Hz, 1 H), 7.23 - 7.31 (m, 1 H), 7.11 - 7.18 (m, 1 H), 7.04 - 7.11 (m, 2 H), 6.94 (d, 
J=3.9 Hz, 2 H), 5.49 (d, J=7.4 Hz, 1 H), 4.13 (s, 3 H), 3.65 (s, 3 H), 3.48 - 3.53 (m, 2 H). 
13CNMR (101MHz, CDCl3)  ppm = 182.0, 171.1, 142.2, 136.1, 127.4, 127.3, 126.2, 
123.1, 122.1, 119.5, 118.6, 111.2, 109.6, 57.2, 52.5, 38.0, 27.0. HRMS-ESI (m/z): 
[M+H]+ calcd. for C17H19N4O2S: 343.1223, found, 343.1238.
 
Methyl 2-(1-benzyl-1H-imidazole-2-carbothioamido)propanoate (1.4e) 
 
18 

Compound 1.4e was prepared from compound 1.3b and alanine methyl ester 
hydrochloride according to general procedure B to afford 1.4e as yellow oil (94% yield).
1HNMR (400MHz, CDCl3)  ppm = 9.85 (d, J=7.0 Hz,  1 H), 7.23 - 7.38 (m, 3 H), 7.17 
(d, J=7.0 Hz, 2 H), 7.03 (s, 1 H), 6.96 (s, 1 H), 6.05 (s, 2 H), 5.01 - 5.27 (m, 1 H), 3.76 (s, 
3 H), 1.58 (d, J=7.4 Hz, 3 H). 13CNMR (101MHz, CDCl3)  ppm = 182.1, 172.1, 142.1, 
136.6, 128.7, 127.8, 127.6, 126.9, 126.1, 52.5, 52.4, 52.1, 17.1. HRMS-ESI (m/z): 
[M+H]+ calcd. for C15H18N3O2S: 304.1114, found, 304.1107.
 
Methyl 2-(1-benzyl-1H-imidazole-2-carbothioamido)-4-methylpentanoate 
(1.4f) 
 
Compound 1.4f was prepared from compound 1.3b and leucine methyl ester 
hydrochloride according to general procedure B to afford 1.4f as yellow oil (63% yield).
1HNMR (400MHz, CDCl3)  ppm = 9.69 (d, J=7.0 Hz,  1 H), 7.22 - 7.39 (m, 3 H), 7.18 
(d, J=7.0 Hz, 2 H), 7.04 (s, 1 H), 6.96 (s, 1 H), 6.06 (d, J=6.2 Hz, 2 H), 5.21 (d, J=7.0 Hz, 
1 H), 3.74 (s, 3 H), 1.81 - 1.89 (m, 2 H), 1.68 - 1.81 (m, 1 H), 0.97 (dd, J=10.5, 6.6 Hz, 6 
H). 13CNMR (101MHz, CDCl3)  ppm = 182.5, 171.8, 142.1, 136.5, 128.7, 127.8, 127.6, 
126.8, 126.1, 55.3, 52.4, 52.1, 40.6, 25.0, 22.7 22.2. HRMS-ESI (m/z): [M+H]+ calcd. for 
C18H24N3O2S: 346.1584, found, 346.1601.
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Methyl 2-(1-benzyl-1H-imidazole-2-carbothioamido)-3-phenylpropanoate 
(1.4g) 
 
Compound 1.4g was prepared from compound 1.3b and phenylalaine methyl ester 
hydrochloride according to general procedure B to afford 1.4g as yellow oil (88% yield).
1HNMR (400MHz, CDCl3)  ppm = 9.79 (d, 1 H), 7.21 - 7.41 (m, 6 H), 7.17 (d, J=7.0 Hz, 
4 H), 6.94 - 7.07 (m, 2 H), 5.97 - 6.17 (m, 2 H), 5.48 (d, J=7.0 Hz, 1 H), 3.71 (s, 3 H), 
3.23 - 3.42 (m, 2 H). 13CNMR (101MHz, CDCl3)  ppm = 182.1, 170.7, 142.1, 136.6, 
135.7, 129.2, 128.7, 128.6, 127.8, 127.5, 127.1, 127.0, 126.2, 57.7, 52.4, 52.1, 37.0. 
HRMS-ESI (m/z): [M+H]+ calcd. for C21H22N3O2S: 380.1427, found, 380.1411.
  
Methyl 2-(1-benzyl-1H-imidazole-2-carbothioamido)-3-(1H-indol-3-
yl)propanoate (1.4h) 
 
Compound 1.4h was prepared from compound 1.3b and tryptophan methyl ester 
hydrochloride according to general procedure B to afford 1.4h as yellow foamy powder 
(72% yield). 1HNMR (400MHz, CDCl3)  ppm = 9.75 (d, 1 H), 8.11 (br. s., 1 H), 7.56 (d, 
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J=7.8 Hz, 1 H), 7.26 - 7.37 (m, 4 H), 7.12 - 7.21 (m, 3 H), 7.03 - 7.10 (m, 2 H), 6.97 (d, 
J=14.8 Hz, 2 H), 5.97 - 6.16 (m, 2 H), 5.50 (d, J=7.4 Hz, 1 H), 3.65 (s, 3 H), 3.51 (t, 
J=6.4 Hz, 2 H). 13CNMR (101MHz, CDCl3)  ppm = 182.1, 171.1, 142.3, 136.7, 136.0, 
128.7, 127.8, 127.6, 127.3, 127.0, 126.1, 123.0, 122.1, 119.5, 118.7, 111.1, 109.8, 57.1, 
52.4, 52.1, 26.8. HRMS-ESI (m/z): [M+H]+ calcd. for C23H23N4O2S: 419.1536, found, 
419.1553.
 
Methyl 2-(1-isobutyl-1H-imidazole-2-carbothioamido)propanoate (1.4i) 
 
Compound 1.4i was prepared from compound 1.3c and alanine methyl ester 
hydrochloride according to general procedure B to afford 1.4i as yellow oil (85% yield).
1HNMR (400MHz, CDCl3)  ppm = 9.79 (d, J=4.4 Hz,  1 H), 7.00 (d, J=5.9 Hz, 2 H), 
5.15 (t, J=7.0 Hz, 1 H), 4.50 (t, J=7.8 Hz, 2 H), 3.76 (s, 3 H), 2.13 - 2.32 (m, 1 H), 1.58 
(d, J=7.0 Hz, 3 H), 0.89 (d, J=7.0 Hz, 6 H). 13CNMR (101MHz, CDCl3)  ppm = 182.1, 
172.1, 141.9, 126.9, 125.9, 56.1, 52.5, 52.3, 29.7, 19.6, 17.1. HRMS-ESI (m/z): [M+H]+ 
calcd. for C12H20N3O2S: 270.1271, found, 270.1277.
 
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Methyl 2-(1-isobutyl-1H-imidazole-2-carbothioamido)-4-methylpentanoate 
(1.4j) 
 
Compound 1.4j was prepared from compound 1.3c and leucine methyl ester 
hydrochloride according to general procedure B to afford 1.4j as yellow oil (81% yield).
1HNMR (400MHz, CDCl3)  ppm = 9.66 (d, J=6.0 Hz,  1 H), 6.99 (d, J=4.7 Hz, 2 H), 
5.19 (d, J=7.0 Hz, 1 H), 4.50 (dd, J=9.8, 7.4 Hz, 2 H), 3.73 (s, 3 H), 2.15 - 2.31 (m, 1 H), 
1.80 - 1.87 (m, 2 H), 1.70 - 1.79 (m, 1 H), 0.95 (dd, J=10.2, 6.2 Hz, 6 H), 0.88 (dd, J=6.8, 
2.5 Hz, 6 H). 13CNMR (101MHz, CDCl3)  ppm = 182.6, 171.9, 141.9, 126.9, 126.0, 
56.1, 55.3, 52.3, 40.6, 29.7, 25.0, 22.6, 22.1, 19.7, 19.6. HRMS-ESI (m/z): [M+H]+ calcd. 
for C15H26N3O2S: 312.174, found, 312.1757.
 
Methyl 2-(1-isobutyl-1H-imidazole-2-carbothioamido)-3-phenylpropanoate 
(1.4k) 
 
Compound 1.4k was prepared from compound 1.3c and phenylalanine methyl 
ester hydrochloride according to general procedure B to afford 1.4k as yellow oil (95% 
yield). 1HNMR (400MHz, CDCl3)  ppm = 9.78 (d, J=7.2 Hz,  1 H), 7.13 - 7.33 (m, 5 H), 
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6.98 (d, J=6.2 Hz, 2 H), 5.45 (d, J=7.4 Hz, 1 H), 4.50 (d, J=7.4 Hz, 2 H), 3.69 (s, 3 H), 
3.31 (dd, J=9.4, 6.2 Hz, 2 H), 2.13 - 2.28 (m, 1 H), 0.88 (dd, J=6.6, 3.1 Hz, 6 H). 
13CNMR (101MHz, CDCl3)  ppm = 182.1, 170.7, 141.8, 135.7, 129.2, 128.5, 127.1, 
126.9, 126.0, 57.7, 56.1, 52.3, 37.1, 29.7, 19.6. HRMS-ESI (m/z): [M+H]+ calcd. for 
C18H24N3O2S: 346.1584, found, 346.1569.
 
Methyl 3-(1H-indol-3-yl)-2-(1-isobutyl-1H-imidazole-2-
carbothioamido)propanoate (1.4l) 
 
Compound 1.4l was prepared from compound 1.3c and tryptophan methyl ester 
hydrochloride according to general procedure B to afford 1.4l as yellow foamy solid (70% 
yield). 1HNMR (400MHz, CDCl3)  ppm = 9.87 (d, J=7.6 Hz,  1 H), 8.26 (br. s., 1 H), 
7.56 (d, J=7.8 Hz, 1 H), 7.21 - 7.32 (m, 1 H), 7.02 - 7.17 (m, 3 H), 6.94 (s, 2 H), 5.49 (d, 
J=7.4 Hz, 1 H), 4.48 (d, J=7.0 Hz, 2 H), 3.64 (s, 3 H), 3.51 (d, J=5.5 Hz, 2 H), 2.14 - 2.30 
(m, 1 H), 0.88 (d, J=6.6 Hz, 6 H). 13CNMR (101MHz, CDCl3)  ppm = 181.9, 171.1, 
141.8, 136.1, 127.3, 126.7, 125.7, 123.1, 122.0, 119.4, 118.6, 111.1, 109.7, 57.3, 56.1, 
52.4, 29.7, 26.9, 19.6. HRMS-ESI (m/z): [M+H]+ calcd. for C20H25N4O2S: 385.1693, 
found, 385.1699. 
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5-Methyl-3-(1-methyl-1H-imidazol-2-yl)-4,5-dihydro-1,2,4-triazin-6(1H)-one 
(1.5a)15 
 
General Procedure C. To a solution of compound 1.4a (754 mg, 3.32 mmol) in 
25 mL of 1,4-dioxane at room temperature (RT) under nitrogen was added hydrazine 
hydrate (830 mg, 16.6 mmol), then the reaction solution was heated up to reflux for 
24hrs. The solvent was then evaporated in vacuum, and the resulting residue was purified 
by flash column chromatography to afford compound 1.5a as an off-white solid (315 mg, 
49%). 1HNMR (400MHz, DMSO-d6)  ppm = 10.46 (s, 1 H), 7.28 (s, 1 H), 7.21 (s, 1 H), 
6.97 (s, 1 H), 3.90 (q, J=6.6 Hz, 1 H), 3.82 (s, 3 H), 1.26 (d, J=6.6 Hz, 3 H). 13CNMR 
(101MHz, DMSO-d6)  ppm = 164.7, 139.8, 138.5, 127.2, 125.8, 48.7, 36.0, 19.0. 
HRMS-ESI (m/z): [M+H]+ calcd. for C8H12N5O: 194.1036, found, 194.1046. 
 
5-Isobutyl-3-(1-methyl-1H-imidazol-2-yl)-4,5-dihydro-1,2,4-triazin-6(1H)-one 
(1.5b) 
 
Compound 1.5b was prepared from compound 1.4b according to general 
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procedure C to afford 1.5b as an off-white solid (79% yield). 1HNMR (400MHz, DMSO-
d6)  ppm = 10.49 (s, 1 H), 7.28 (s, 1 H), 7.14 (s, 1 H), 6.96 (s, 1 H), 3.78 - 3.86 (m, 4 H), 
1.69 - 1.83 (m, 1 H), 1.38 - 1.47 (m, 2 H), 0.87 (d, J=6.6 Hz, 6 H). 13CNMR (101MHz, 
DMSO-d6)  ppm = 164.3, 139.7, 138.6, 127.5, 125.9, 51.4, 41.5, 35.9, 23.9, 23.2, 22.6. 
HRMS-ESI (m/z): [M+H]+ calcd. for C11H18N5O: 236.1506, found, 236.152. 
  
5-Benzyl-3-(1-methyl-1H-imidazol-2-yl)-4,5-dihydro-1,2,4-triazin-6(1H)-one 
(1.5c) 
 
Compound 1.5c was prepared from compound 1.4c according to general 
procedure C to afford 1.5c as an off-white solid (57% yield). 1HNMR (400MHz, DMSO-
d6)  ppm = 10.41 (s, 1 H), 7.14 - 7.26 (m, 6 H), 7.05 (s, 1 H), 6.95 (s, 1 H), 4.21 (t, J=4.7 
Hz, 1 H), 3.67 (s, 3 H), 2.97 (dd, J=14.4, 5.1 Hz, 2 H). 13CNMR (101MHz, DMSO-d6)  
ppm = 162.9, 139.4, 138.5, 137.0, 130.3, 128.4, 127.4, 126.8, 125.6, 54.4, 38.7, 35.8. 
HRMS-ESI (m/z): [M+H]+ calcd. for  C14H16N5O: 270.1349, found, 270.1362. 
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5-((1H-indol-3-yl)methyl)-3-(1-methyl-1H-imidazol-2-yl)-4,5-dihydro-1,2,4-
triazin-6(1H)-one (1.5d) 
 
Compound 1.5d was prepared from compound 1.4d according to general 
procedure C to afford 1.5d as an off-white solid (76% yield). 1HNMR (400MHz, DMSO-
d6)  ppm = 10.84 (br. s., 1 H), 10.36 (s, 1 H), 7.50 (d, J=8.2 Hz, 1 H), 7.29 (d, J=8.2 Hz, 
1 H), 7.20 (s, 1 H), 7.11 (d, J=1.6 Hz, 1 H), 6.81 - 7.05 (m, 4 H), 4.19 (t, J=4.9 Hz, 1 H), 
3.60 (s, 3 H), 3.11 - 3.21 (m, 1 H), 2.98 - 3.10 (m, 1 H). 13CNMR (101MHz, DMSO-d6)  
ppm = 163.5, 139.4, 138.6, 136.4, 127.9, 127.3, 125.6, 124.6, 121.2, 118.9, 118.5, 111.6, 
109.2, 53.8, 35.7, 28.9. HRMS-ESI (m/z): [M+H]+ calcd. for  C16H17N6O: 309.1458, 
found, 309.1463. 
  
3-(1-Benzyl-1H-imidazol-2-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-6(1H)-one 
(1.5e) 
 
Compound 1.5e was prepared from compound 1.4e according to general procedure C 
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to afford 1.5e as a light yellow solid (58% yield). 1HNMR (400MHz, DMSO-d6)  ppm = 
10.45 (s, 1 H), 7.38 (s, 1 H), 7.16 - 7.35 (m, 6 H), 7.02 (s, 1 H), 5.54 - 5.67 (m, 2 H), 3.89 (q, 
J=6.5 Hz, 1 H), 1.24 (d, J=6.6 Hz, 3 H). 13CNMR (101MHz, DMSO-d6)  ppm = 164.6, 
139.8, 138.3, 128.9, 128.0, 127.9, 127.8, 124.9, 50.5, 48.8, 19.0. HRMS-ESI (m/z): [M+H]+ 
calcd. for  C14H16N5O: 270.1349, found, 270.1351.  
 
3-(1-Benzyl-1H-imidazol-2-yl)-5-isobutyl-4,5-dihydro-1,2,4-triazin-6(1H)-one 
(1.5f) 
 
Compound 1.5f was prepared from compound 1.4f according to general procedure C 
to afford 1.5f as a light yellow solid (47% yield). 1HNMR (400MHz, CDCl3)  ppm = 8.58 
(s, 1 H), 7.23 - 7.38 (m, 3 H), 7.15 (d, J=7.0 Hz, 2 H), 7.04 (s, 1 H), 6.92 (s, 1 H), 6.47 (br. s., 
1 H), 5.52 - 5.69 (m, 2 H), 4.08 (dd, J=7.4, 4.7 Hz, 1 H), 1.81 - 1.94 (m, 1 H), 1.69 - 1.78 (m, 
1 H), 1.59 - 1.68 (m, 1 H), 0.96 (dd, J=9.0, 6.6 Hz, 6 H). 13CNMR (101MHz, CDCl3)  ppm 
= 164.6, 139.4, 137.9, 136.6, 128.8, 128.0, 127.8, 127.5, 123.9, 51.7, 51.6, 41.5, 23.9, 23.1, 
21.5. HRMS-ESI (m/z): [M+H]+ calcd. for  C17H22N5O: 312.1819, found, 312.1827.  
  
  
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5-Benzyl-3-(1-benzyl-1H-imidazol-2-yl)-4,5-dihydro-1,2,4-triazin-6(1H)-one 
(1.5g) 
 
Compound 1.5g was prepared from compound 1.4g according to general 
procedure C to afford 1.5g as a white foamy powder (52% yield). 1HNMR (400MHz, 
CDCl3)  ppm = 8.50 (s, 1 H), 7.17 - 7.42 (m, 8 H), 7.10 (d, J=7.4 Hz, 2 H), 7.02 (s, 1 H), 
6.89 (s, 1 H), 6.52 (br. s., 1 H), 5.45 - 5.60 (m, 2 H), 4.28 - 4.38 (m, 1 H), 3.24 (dd, 
J=13.7, 3.5 Hz, 1 H), 3.01 (dd, J=13.7, 8.2 Hz, 1 H). 13CNMR (101MHz, CDCl3)  ppm 
= 163.4, 139.0, 137.6, 136.5, 135.7, 129.7, 128.8, 128.7, 127.9, 127.5, 127.4, 127.0, 
123.8, 55.0, 51.6, 39.3. HRMS-ESI (m/z): [M+H]+ calcd. for  C20H20N5O: 346.1662, 
found, 346.1673. 
 
5-((1H-indol-3-yl)methyl)-3-(1-benzyl-1H-imidazol-2-yl)-4,5-dihydro-1,2,4-
triazin-6(1H)-one (1.5h) 
 
Compound 1.5h was prepared from compound 1.4h according to general 
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procedure C to afford 1.5h as an off-white solid (68% yield). 1HNMR (400MHz, CDCl3) 
 ppm = 8.48 (s, 1 H), 8.25 (br. s., 1 H), 7.64 (d, J=7.8 Hz, 1 H), 7.22 - 7.38 (m, 4 H), 
6.96 - 7.21 (m, 6 H), 6.84 (s, 1 H), 6.64 (br. s., 1 H), 5.35 - 5.53 (m, 2 H), 4.36 (d, J=5.1 
Hz, 1 H), 3.44 (dd, J=14.6, 2.9 Hz, 1 H), 3.13 (dd, J=14.4, 8.2 Hz, 1 H). 13CNMR 
(101MHz, CDCl3)  ppm = 163.9, 138.9, 137.6, 136.4, 136.3, 128.8, 128.0, 127.5, 127.1, 
127.0, 123.8, 123.6, 122.1, 119.4, 118.7, 111.1, 109.6, 53.8, 51.6, 29.2. HRMS-ESI 
(m/z): [M+H]+ calcd. for  C22H21N6O: 385.1771, found, 385.1781. 
 
3-(1-Isobutyl-1H-imidazol-2-yl)-5-methyl-4,5-dihydro-1,2,4-triazin-6(1H)-one 
(1.5i) 
 
Compound 1.5i was prepared from compound 1.4i according to general procedure 
C to afford 1.5i as an off-white solid (67% yield). 1HNMR (400MHz, CDCl3)  ppm = 
9.14 (br. s., 1 H), 7.04 (s, 1 H), 6.96 (s, 1 H), 6.57 (br. s., 1 H), 4.16 (d, J=7.0 Hz, 3 H), 
2.04 - 2.22 (m, 1 H), 1.48 (d, J=6.6 Hz, 3 H), 0.89 (d, J=6.6 Hz, 6 H). 13CNMR 
(101MHz, CDCl3)  ppm = 165.2, 139.8, 137.8, 127.0, 124.6, 55.4, 49.0, 29.5, 19.7, 18.7. 
HRMS-ESI (m/z): [M+H]+ calcd. for  C11H18N5O: 236.1506, found, 236.1517. 
 
  
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5-Isobutyl-3-(1-isobutyl-1H-imidazol-2-yl)-4,5-dihydro-1,2,4-triazin-6(1H)-
one (1.5j) 
 
Compound 1.5j was prepared from compound 1.4j according to general procedure 
C to afford 1.5j as an off-white solid (68% yield). 1HNMR (400MHz, CDCl3)  ppm = 
9.00 (s, 1 H), 7.01 (s, 1 H), 6.93 (s, 1 H), 6.53 (br. s., 1 H), 4.10 - 4.22 (m, 2 H), 4.02 - 
4.10 (m, 1 H), 2.04 - 2.17 (m, 1 H), 1.80 - 1.92 (m, 1 H), 1.67 - 1.77 (m, 1 H), 1.56 - 1.66 
(m, 1 H), 0.94 (dd, J=9.8, 6.6 Hz, 6 H), 0.83 - 0.90 (m, 6 H). 13CNMR (101MHz, CDCl3) 
 ppm = 164.9, 139.5, 137.9, 127.2, 124.6, 55.4, 51.6, 41.5, 29.5, 23.9, 23.0, 21.6, 19.8, 
19.7. HRMS-ESI (m/z): [M+H]+ calcd. for  C14H24N5O: 278.1975, found, 278.1991. 
 
5-Benzyl-3-(1-isobutyl-1H-imidazol-2-yl)-4,5-dihydro-1,2,4-triazin-6(1H)-one 
(1.5k) 
 
Compound 1.5k was prepared from compound 1.4k according to general 
procedure C to afford 1.5k as a pink foamy solid (78% yield). 1HNMR (400MHz, CDCl3) 
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 ppm = 8.57 (s, 1 H), 7.14 - 7.34 (m, 5 H), 6.99 (s, 1 H), 6.89 (s, 1 H), 6.48 (br. s., 1 H), 
4.31 (dd, J=7.2, 3.3 Hz, 1 H), 3.97 - 4.14 (m, 2 H), 3.21 (dd, J=13.7, 3.5 Hz, 1 H), 3.01 
(dd, J=13.7, 7.8 Hz, 1 H), 1.91 - 2.05 (m, 1 H), 0.79 - 0.85 (m, 6 H). 13CNMR (101MHz, 
CDCl3)  ppm = 163.4, 139.1, 137.5, 135.8, 129.7, 128.6, 127.0, 126.9, 124.5, 55.4, 55.0, 
39.3, 29.3, 19.7. HRMS-ESI (m/z): [M+Na]+ calcd. for  C17H21N5ONa: 334.1638, 
found, 334.1639. 
 
5-((1H-indol-3-yl)methyl)-3-(1-isobutyl-1H-imidazol-2-yl)-4,5-dihydro-1,2,4-
triazin-6(1H)-one (1.5l) 
 
Compound 1.5l was prepared from compound 1.4l according to general procedure 
C to afford 1.5l as a white foamy solid (72% yield). 1HNMR (400MHz, CDCl3)  ppm= 
8.55 (s, 1 H), 8.36 (br. s., 1 H), 7.63 (d, J=8.2 Hz, 1 H), 7.22 - 7.32 (m, 1 H), 7.07 - 7.17 
(m, 2 H), 7.00 - 7.07 (m, 1 H), 6.96 (s, 1 H), 6.86 (s, 1 H), 6.53 (s, 1 H), 4.33 (dd, J=8.6, 
2.3 Hz, 1 H), 4.01 (d, J=7.4 Hz, 2 H), 3.47 (d, J=3.5 Hz, 1 H), 3.43 (d, J=3.1 Hz, 1 H), 
1.88 - 2.04 (m, 1 H), 0.81 (t, J=6.2 Hz, 6 H). 13CNMR (101MHz, CDCl3)  ppm = 164.1, 
139.2, 137.6, 136.3, 127.1, 126.7, 124.4, 123.8, 122.0, 119.4, 118.7, 111.1, 109.6, 55.4, 
53.7, 29.3, 29.1, 19.7, 19.6. HRMS-ESI (m/z): [M+H]+ calcd. for  C19H23N6O: 
351.1928, found, 351.1926.
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CHAPTER TWO: 
NOVEL BUILDING BLOCKS FOR 18F-RADIOLABELING OF MOLECULAR 
PROBE FOR PET IMAGING  
 
2.1 Introduction 
2.1.1 PET Imaging, Molecular Probe and Radiotracers 
Current imaging techniques including X-rays, ultrasound (US) and magnetic 
resonance imaging (MRI) have many anatomical applications but give very limited 
information on metabolic or molecular events. Accordingly, the development of novel 
approaches to image and monitor real-time molecular events in vivo has seen increasing 
demand[1-4]. One such technique that has been developed is positron emission 
tomography (PET).  PET is a radionuclide based molecular imaging technique, which can 
be used for early detection, characterization, “real time” monitoring of diseases, and 
investigating the efficacy of drugs[5-8]. More recently, it has become an important clinical 
diagnostic and research method as well as a valuable tool in the drug discovery and 
development arena.  
PET imaging techniques rely on the use of exogenous radioactive probe 
(molecular probe) to provide a detectable signal. The probes can be designed as tissue-
based or receptor-based molecules and give a detailed picture of the targeted structure or 
biological processes[9, 10]. A few biologically interesting molecular probes for PET 
imaging have been reported in the last few years and used for diagnostic clinical studies, 
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Scheme 2.6 Ting and co -worker boron-fluorine bond formation strategy for 18F-
radiolabelling.  
 
2.2.3 Silicon-Fluorine Bond Formation 
The silicon-fluorine bond energy ( 570KJ mol-1)22 is much higher than that of 
carbon-fluorine bond (~ 480KJ mol-1), and therefore has drawn the attention of 
radiochemists for its potential in 18F-radiolabelling. The first example was described by 
Rosenthal and coworkers in 1985, Scheme 2.7.  
 
Scheme 2.7 Rosenthal and coworkers silicon-fluorine bond formation strategy for 18F-
radiolabelling.  
 
Another example of this approach was reported by Ting and co-workers23 in 2005, 
a triethoxysilane precursor (ex. biotin derivatives) are reacted with nucleophilic 18F-
fluoride using the carrier potassium hydrogen fluoride (KHF2) to give the anionic 
alkyltetrafluorosilicate, as shown in Scheme 2.8.  
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Scheme 2.8 Ting and co-worker silicon-fluorine bond formation approach for 18F-
radiolabelling.  
 
 
In 2007, Schirrmacher26 and coworkers reported another approach based on the 
trialkylsilane binding sites through 19F/18F isotopic exchange instead of nucleophilic 
substitution of hydroxyl or alkoxy groups, as shown in Scheme 2.9.  
Si Cl
18F
CH3CN, rt
15min
80-95% RCY
Si 18F
Si 19F
18F
CH3CN, rt
15min
isotopic exchange  
Scheme 2.9 Synthesis of [18F]-fluorodi-tert-butylphenylsilyl by 19F/18F isotopic exchange  
 
2.2.4 Aluminium-Fluorine Bond Formation 
The aluminium-fluorine bond also has high bond energy ( 670KJ mol-1)22, 
offering the opportunity for fluoride to act as coordination ligand to aluminium (Al3+). 
The general strategy of this coordinate bond is based on the selective binding of [18F]-
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Figure 2.4 Currently used bifunctional chelators . 
 
2.2.5 Common 18F Reagents for Labelling Peptides, Proteins and 
Oligonucleotides 
Owing to the potentials of biomolecules in the treatment of diseases and 
diagnosis, the application of 18F radiolabelling biomolecules including peptides, 
oligonucleotides and proteins in PET is becoming more important and has drawn the 
attention of radiochemists. The traditional approach using direct radiolabelling of most 
peptides and proteins through nucleophilic [18F] fluoride is not appropriate due to harsh 
reaction conditions such as high temperatures, strong acidic/basic conditions, and longer 
reaction times. The alternative approach of indirect introduction of 18F radioisotope into 
peptides and proteins has been developed in PET imaging. The general strategy is that 
peptides and proteins are reacted with suitable prosthetic 18F groups under mild reaction 
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conditions such as room temperature, aqueous solution and short reaction time. In 
addition, the prosthetic groups in this reaction should be chemo-selective and have no 
adverse effects on the biological properties of peptides and proteins.  
A few prosthetic18F-radiolabelled groups have been reported for labelling 
peptides[31-34], and they are shown in Scheme 2.10. Each method has its own strengths 
and weakness based on the synthesis and reactivity of the target peptide. No general 
protocol is available for the synthesis of radiolabelled peptides. For any particular ligand, 
the best approach is to review several radiolabelling procedures and optimized one to suit 
the particular needs.  
18F labelled peptide or proteins
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Scheme 2.10 Prosthetic reagents for the 18F radiolabelling of peptides, proteins.  
 
Another Approach for the preparation of [18F]-radiolabelled peptides has been 
reported through “Click” chemistry[35, 36], is shown in Scheme 2.11. This technique uses 
Huisgen 1,3-dipolar cycloaddition of terminal alkynes and azides to form 1,2,3-triazoles.  
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Scheme 2.11  “Click chemistry” strategy for the 18F radiolabelling of peptides, proteins.  
 
2.3 Results & Discussions 
2.3.1 Current Challenges in 18F Radiolabelling for Molecular Probe in PET 
Imaging 
One of the main challenges in 18F radiolabelling for PET imaging is the 
development of efficient synthetic methods to introduce 18F into biomolecules, with the 
shortest reaction time possible. Another challenge is to avoid harsh reaction conditions 
(high temperature, high pressure, strong acidic or basic, longer reaction time), especially 
for biomolecules (peptides, proteins). Only a few peptide based 18F-radiopharmaceuticals 
for diagnostic application with PET have entered into clinical trials so far.  
 
2.3.2 Design of the Potential 18F-Radiolabelling Molecular Probe 
In order to explore potential molecular probes for peptides/proteins, the boron-
fluorine bond formation approach attracted our attention due to the bond energy already 
discussed22 (Table 2.2).  
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(Tris) was proposed as building block to introduce 19F/18F into a biomolecule. Tris can be 
converted to the borate ester, and then the empty p orbital on boron will allow for 
additional coordination from a fluoride ion, making the boron ester a fluorine capture 
reagent. The proposed scheme is shown in Figure 2.6.  
 
Figure 2.6 Flow chart of boron ester used as a fluorine capture reagent. 
 
 
2.3.3 Fluorine Introduction Strategy: Building Block  
 
 
Scheme 2.12 Newly discovered strategy for 19F introduction. 
 
 
Tris(hydroxymethyl)aminomethane (Tris) (2.1) was used as building block to 
introduce 19F/18F into biomolecule in our new discovery. The strategy first treated 
commercially available Tris 2.1 with trimethyl borate to give the Tris borate ester 2.2, 
followed by treatment with potassium fluoride in ethanol to afford the potassium salt of 
the boron-fluoride complex adduct 2.3 in quantitative yield, as shown in Scheme 2.12.  
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2.3.4 Fluorine Introduction Strategy: RCOOH Series Substrates  
 
Scheme 2.13 19F introduction into RCOOH series substrates 
 
The strategy to introduce 19F/18F into RCOOH series substrates was initiated with 
coupling RCOOH 2.4 with Tris 2.1 to afford the Tris analogs 2.5. Generally, carboxylic 
acid 2.4 (or amino acid) was coupled with Tris 2.1 through a conventional peptide 
coupling method with HCTU as the coupling reagent. The resulting Tris-OH intermediate 
2.5, was treated with trimethyl borate to give a Tris borate ester. Finally, treatment with 
potassium fluoride in ethanol to afforded the potassium salt of boron-fluoride complex 
adduct 2.6 in quantitative yield, as shown in Scheme 2.13. The preparation of Tris 
analogs compound 2.5 (RCOOH series substrates) is listed in Table 2.3, and the 
following potassium salt of boron-fluoride complex adduct 2.6 is listed in Table 2.4.  
 
Table 2.3 Preparation of RCOOH series compound 2.5
  Compound 2.4 Compound 2.1 Percent yield 
2.5a 3-chlorobenzoic acid Tris 72% 
2.5b Z-Ala-OH Tris 52% 
2.5c Z-Val-OH Tris 66% 
2.5d Z-Phe-OH Tris 81% 
2.5e Z-Typ-OH Tris 42% 
2.5f Boc-Lys-Z-OH Tris 51% 
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Table 2.4 Preparation of boron-fluoride complex adduct 2.6 forRCOOH series substrates 
  Compound 2.5 Percent yield 
2.6a 2.5a 100% 
2.6b 2.5b 100% 
2.6c 2.5c 100% 
2.6d 2.5d 100% 
2.6e 2.5e 100% 
2.6f 2.5f 100% 
 
 
 
2.3.5 Fluorine Introduction Strategy: RNH2 Series Substrates  
 
Scheme 2.14 19F introduction into RNH2 series substrates 
 
 
A parallel strategy to introduce 19F/18F into a RNH2 series substrate was also 
devised following a functional group conversion. Firstly, primary amine 2.7 was reacted 
with succinic anhydride 2.8 to give the carboxylic acid 2.9. Then compound 2.9 was 
coupled with Tris 2.1 through the conventional peptide coupling method with HCTU as 
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the coupling reagent. The resulting Tris-OH intermediate 2.10, was treated with trimethyl 
borate to give the Tris borate ester which was finally, treated with potassium fluoride in 
ethanol to afford the potassium salt of boron-fluoride complex adduct 2.11 in quantitative 
yield, as shown in Scheme 2.14. The preparation of Tris analogs compound 2.10 (RNH2 
series substrates) is listed in Table 2.5, and the following potassium salt of boron-fluoride 
complex adduct 2.11 is listed in Table 2.6.  
 
Table 2.5 Preparation of RNH2 series compounds 2.10. 
  Compound 2.7 Compound 2.8 Compound 2.1 Percent yield 
2.10a 2,4-Dimethoxybenzylamine Succinic anhydride Tris 41% 
2.10b 4-Methoxybenzylamine Succinic anhydride Tris 35% 
2.10c 
2-(3,4-
dimethoxyphenyl)ethanamine Succinic anhydride Tris 56% 
2.10d Benzylamine Succinic anhydride Tris 68% 
2.10e H-Trp-OMe Succinic anhydride Tris 36% 
 
 
Table 2.6 Preparation of boron-fluoride complex adducts 2.11 forRNH2 series substrates.  
  Compound 2.10 Percent yield 
2.11a 2.10a 100% 
2.11b 2.10b 100% 
2.11c 2.10c 100% 
2.11d 2.10d 100% 
2.11e 2.10e 100% 
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2.3.6 New Approach for Boron-Fluorine Bond Formation 1 
 
 
Scheme 2.15 New Approach for 19F introduction. 
 
 
 Scheme 2.16 New Approach for 19F introduction based on ion-exchange resin. 
 
 
 
1,1,1-Tris(hydroxymethyl)ethane (2.12) was also used as a substrate to introduce 
19F/18F into a biomolecule. The approach first treated commercially available reagent 2.12 
with trimethyl borate to give the Tris borate ester 2.13. Next, the fluoride ion was added 
through an ion-exchange resin to form a fluoride adduct on the resin, and then the Tris 
borate ester 2.13 was added onto resin. Following elution with ammonium bicarbonate, 
the ammonium salt of the desired boron-fluoride complex adduct 2.14 was isolated in 
quantitative yield, Schemes 2.15 & 2.16.  
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2.3.7 New Approach for Boron-Fluorine Bond Formation 2 
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Scheme 2.17 New Approach for 19F introduction. 
 
 
Scheme 2.18 New Approach for 19F introduction based on ion-exchange resin. 
 
Another novel approach for the introduction of the fluoride ion to boron ester 
involved ion-exchange resin, Tris 2.1 was reacted with succinic anhydride 2.8 to give 
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compound 2.15. Then compound 2.15 was attached to ion-exchange resin. The resulting 
intermediate on resin was treated with trimethyl borate to yield the Tris borate ester 2.16. 
Finally the fluoride ion was added into ion-exchange resin to form the boron-fluoride 
adduct. Elution with ammonium bicarbonate afforded the ammonium salt of boron-
fluoride complex adduct 2.17 in quantitative yield, Scheme 2.17 & 2.18.  
 
2.3.8 Fluorine Capture Application in PET Probe  
2.3.8.1 Folic Acid as a Targeting Ligand 
Folate receptors (FR) have very limited expression on healthy cells, but are 
commonly expressed in cancer cells. For example, folate receptors are found in epithelial 
cancers among ovary, mammary gland, colon, lung, prostate, nose, throat and brain, 
which make them to be good drug targets[37-41]. As the development of targeted 
pharmaceuticals and drug delivery, folate-drug conjugate (as shown in Figure 2.7) 
become well studied example in receptor targeted therapeutics, because folic acid can 
selectively binds to the pathologic cell and delivers attached drugs into cell while normal 
tissues lacking FR will not get involved42. 
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PET imaging agents50. Among all the other radionuclides, technetium-99m (99mTc) has 
been shown to be the best diagnostic radionuclide, and folate targeted 99mTc-
radiopharmaceuticals have been successfully used to image human cancers[51-54]. 
However, the current (first generation) folate conjugates of MRI and PET imaging probes 
have enjoyed very limited success. Opportunities for the design of novel folate-targeted 
imaging probe have arisen from the demand for development of higher resolution and 
more sensitive imaging technologies.  
 
2.3.8.2 Synthesis of New Folate-Targeted Molecular Probe 
 
Scheme 2.19 New Approach for 19F introduction into folic acid. 
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Scheme 2.20 New Approach for the synthesis of folic acid molecular probe. 
 
 
This strategy introduced 19F/18F into folic acid. First, folic acid was coupled with 
Tris to afford a Tris-OH intermediate through traditional peptide coupling method with 
HCTU as coupling reagent. Next, the Tris-OH intermediate was treated with trimethyl 
borate to afford Tris borate ester. The fluoride ion was added to an ion-exchange resin to 
form fluoride adduct, and then the Tris borate ester is added onto resin. Finally, elution 
with ammonium bicarbonate afforded the desired ammonium salt of the boron-fluoride 
complex adduct, a novel folic acid molecular probe. This strategy is shown in Scheme 
2.19 & 2.20.  
 
2.4 Conclusion 
In this chapter, we have successfully developed the general protocol to introduce 
fluorine into peptide-based molecules using the novel building block 
Tris(hydroxymethyl)aminomethane (Tris). This approach allows us to introduce fluorine 
into biomolecules within 30 minutes based on the resin technology. The novel building 
block offer us several advantages. First, short reaction time for 18F introduction into 
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molecular probe; second, no harsh reaction conditions applied for this series of reactions, 
such as room temperature, no strong acidic or strong basic condition; third, 18F can be 
introduced in the last step of the synthetic sequence, which give the radiochemists  
enough time to prepare the precursor of molecular probe; fourth, Tris could be a very 
versatile building block for peptides, non-peptides, proteins and amines, which can be 
easily introduced fluorine-18 as molecular  probe for PET imaging. Finally, Tris could 
have a lot of variants as the next generation of building blocks for PET imaging.  
 
2.5 Experimental Section 
2.5.1 Materials and Methods 
Organic and inorganic reagents (ACS grade) and solvents were obtained from 
commercial sources and used without further purification, unless otherwise noted. 
Moisture and air-sensitive reactions were carried out under an inert atmosphere of 
nitrogen. Thin layer chromatography (TLC) was performed on glass plates pre-coated 
with 0.25mm thickness of silica gel (60F-254) with fluorescent indicator. Column 
chromatographic purification was performed using silica gel 60 Å, (# 70-230 mesh). All 
1H NMR , 13C NMR, 19F-NMR, 11B-NMR spectra were recorded on Varian INOVA 400, 
500 MHz or Bruker 250 MHz spectrometer at 25 oC in chloroform-d (CDCl3) or dimethyl 
sulfoxide-d6 (DMSO-d6), unless otherwise specified. Chemical shifts are reported in parts 
per million (ppm) relative to internal standard tetramethylsilane (TMS). Multiplicity is 
expressed as (s = singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, or m = 
multiplet) and the values of coupling constants ( J ) are given in Hertz (Hz). High 
Resolution Mass Spectrometry (HRMS) spetra were carried out on an Agilent 6540 
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QToF in the ESI-TOF mode.
 
2.5.2 Experimental Procedures 
Potassium salt of boron-fluoride complex adduct (2.3)55 
 
To a solution of tris(hydroxymethyl)aminomethane (Tris) (2.1) (1.09g, 9.0mmol) 
in dichloromethane (DCM) (30 mL) was added trimethyl borate (B(OMe)3) (0.935 g, 9.0 
mmol) at room temperature under nitrogen. The reaction mixture was then heated to 
reflux for 5 hrs. The reaction mixture was then concentrated in vacuo to remove all the 
solvent. The resulting crude compound 2.2 (Tris borate ester) was dried overnight under 
high vacuum, and directly used for the next step without further purification. Then Tris 
borate ester 2.2 was dissolved in anhydrous ethanol (EtOH), and potassium fluoride (KF) 
(1.0 eqv.) was added, the resulting suspension was stirred at room temperature (RT) 
overnight. The reaction mixture was then concentrated in vacuo to remove all the solvent 
and, the crude was then dried overnight under high vacuum to afford compound 2.3 
(potassium salt of boron-fluoride complex adduct 2.3) as a white solid in quantitative 
yield. 1HNMR (400MHz, METHANOL-d4) ppm = 3.65 (s, 6 H). 13CNMR (125.6MHz, 
METHANOL-d4) ppm = 61.3, 59.6. 19FNMR (376MHz, METHANOL-d4) ppm = -
154.9. 11BNMR (80.2MHz, METHANOL-d4) ppm = 1.01. HRMS-ESI (m/z): calcd. for 
C4H8[11B]FNO3: 148.0587, found, 148.0586.  
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3-Chloro-N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)benzamide (2.5a) 
 
General Procedure A. To a solution of 3-chlorobenzoic acid (1.01g, 6.45mmol) 
in DMF (30mL) was added T3P (2.70g, 8.49mmol) or HCTU (1.1 eqv.) at RT under N2, 
followed by triethylamine (TEA) (1.2mL, 1.3eqv.). The mixture was stirred for 5mins, 
then Tris (2.1) (3.50g, 28.89mmol) was added in several portions at RT and, after that, 
the mixture was stirred at RT overnight. Once the reaction was completed, the reaction 
solution was concentrated to remove all the solvents. The resulting residue was extracted 
with hot ethyl acetate (EtOAc), sequentially washed with sat. sodium bicarbonate 
solution, brine. Then the organic layer was dried over sodium sulfate (Na2SO4) and, 
concentrated to yield crude product.  The resulting crude was then purified by flash 
column chromatography (silica gel, 100% EtOAc as eluent) to afford compound 2.5a as a 
white powder (1.21 g, 72%). 1HNMR (400MHz, DMSO-d6) ppm = 3.65 (d, J=5.86 Hz, 
6 H), 4.64 (t, J=6.05 Hz, 3 H), 7.36 (s, 1 H), 7.42 - 7.48 (m, 1 H), 7.55 (dd, J=8.20, 1.17 
Hz, 1 H), 7.71 (d, J=7.81 Hz, 1 H), 7.81 (t, J=1.76 Hz, 1 H). 13CNMR (101MHz, DMSO-
d6) ppm = 166.2, 137.8, 133.3, 131.2, 130.5, 127.7, 126.6, 63.4, 60.5. HRMS-ESI 
(m/z): [M+H]+ calcd. for C11H15ClNO4: 260.0684, found, 260.0693.  
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(S)-benzyl (1-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-1-
oxopropan-2-yl)carbamate (2.5b) 
 
Compound 2.5b was prepared from Z-Ala-OH and Tris (2.1) according to general 
procedure A to afford 2.5b as a white solid (52% yield). 1HNMR (400MHz, DMSO-d6)  
ppm = 1.13 - 1.22 (m, 3 H), 3.5(s, 6H), 4.05 (quin, J=7.22 Hz, 1 H), 4.68 (br. s., 3 H), 
4.97 - 5.05 (m, 2 H), 7.14 (s, 1 H), 7.25 - 7.40 (m, 5 H), 7.47 (d, J=7.03 Hz, 1 H). 
13CNMR (101MHz, DMSO-d6)  ppm = 173.8, 156.1, 137.4, 128.8, 128.2, 128.1, 65.9, 
62.3, 60.7, 51.0, 18.7. HRMS-ESI (m/z): [M+H]+ calcd. for C15H23N2O6: 327.1551, 
found, 327.1544.  

(S)-benzyl (1-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-3-
methyl-1-oxobutan-2-yl)carbamate (2.5c) 
 
Compound 2.5c was prepared from Z-Val-OH and Tris (2.1) according to general 
procedure A to afford 2.5c as a white solid (66% yield). 1HNMR (400MHz, D2O)  ppm 
= 0.67 - 0.96 (m, 6 H), 1.79 - 2.06 (m, 1 H), 3.49 (br. s., 1 H), 3.62 (br. s., 6 H), 3.79 (d, 
J=6.64 Hz, 1 H), 5.0(s., 2H), 7.29 (br. s., 5 H). 13CNMR (101MHz, D2O)  ppm = 174.4, 
158.1, 136.4, 128.7, 128.3, 127.5, 67.0, 61.9, 61.2, 60.4, 29.9, 18.3. HRMS-ESI (m/z): 
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[M+H]+ calcd. for C17H27N2O6: 355.1864, found, 355.1866.  
 
(S)-benzyl (1-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-1-oxo-3-
phenylpropan-2-yl)carbamate (2.5d) 
 
Compound 2.5d was prepared from Z-Phe-OH and Tris (2.1) according to general 
procedure A to afford 2.5d as a white solid (81% yield). 1HNMR (400MHz, DMSO-d6)  
ppm = 2.66 - 2.79 (m, 1 H), 3.00 (dd, J=13.67, 3.91 Hz, 1 H), 3.51(br. s., 9H), 4.23 - 4.32 
(m, 1 H), 4.93 (s, 2 H), 7.17 - 7.35 (m, 10 H), 7.51 (d, J=8.20 Hz, 1 H), 8.04 (br. s., 1 H). 
13CNMR (101MHz, DMSO-d6)  ppm = 172.8, 156.2, 138.5, 137.4, 129.6, 128.7, 128.4, 
128.0, 127.8, 126.6, 65.6, 62.5, 60.8, 56.9, 38.0. HRMS-ESI (m/z): [M+H]+ calcd. for 
C21H27N2O6: 403.1864, found, 403.1870.  
 
(S)-benzyl (1-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-3-(1H-
indol-3-yl)-1-oxopropan-2-yl)carbamate (2.5e) 
H
NCbz N
H
O OH
OH
OH
HN
 
Compound 2.5e was prepared from Z-Tryp-OH and Tris (2.1) according to 
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general procedure A to afford 2.5e as a white solid (42% yield). 1HNMR (400MHz, 
DMSO-d6)  ppm = 2.83 - 2.97 (m, 1 H), 3.07 - 3.14 (m, 1 H), 3.52 (br. s.,  9H), 4.24 - 
4.34 (m, 1 H), 4.89 - 4.98 (m, 2 H), 6.90 - 7.01 (m, 1 H), 7.01 - 7.10 (m, 1 H), 7.14 (s, 1 
H), 7.19 - 7.38 (m, 6 H), 7.44 (d, J=7.81 Hz, 1 H), 7.55 - 7.62 (m, 1 H), 8.06 (br. s., 1 H), 
10.69 - 10.94 (m, 1 H). 13CNMR (101MHz, DMSO-d6)  ppm = 173.1, 156.3, 137.4, 
136.5, 128.8, 128.7, 128.0, 127.8, 124.1, 121.2, 118.8, 118.6, 111.7, 110.6, 65.7, 62.5, 
60.8, 56.5, 28.2. HRMS-ESI (m/z): [M+H]+ calcd. for C23H28N3O6: 442.1973, found, 
442.1973.  
 
(S)-benzyl tert-butyl (6-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-
yl)amino)-6-oxohexane-1,5-diyl)dicarbamate (2.5f) 
H
NBoc N
H
O OH
OH
OH
NHCbz  
Compound 2.5f was prepared from Boc-Lys-Z-OH and Tris (2.1) according to 
general procedure A to afford 2.5f as a white solid (51% yield). 1HNMR (400MHz, 
DMSO-d6) ppm = 1.25 (d, J=7.03 Hz, 2 H), 1.35 (s, 11 H), 1.42 - 1.62 (m, 2 H), 2.94 
(d, J=6.25 Hz, 2 H), 3.51 (br. s., 6 H), 3.81 (d, J=3.51 Hz, 3 H), 4.09 (d, J=6.25 Hz, 1 H), 
4.98 (s, 2 H), 6.93 - 7.13 (m, 1 H), 7.15 - 7.25 (m, 1 H), 7.26 - 7.39 (m, 5 H), 7.98 (br. s., 
1 H). 13CNMR (101MHz, DMSO-d6) ppm = 173.6, 156.5, 155.9, 137.7, 128.8, 128.1, 
78.7, 65.5, 62.3, 60.6, 55.4, 31.7, 29.5, 28.6, 23.2, 10.7. HRMS-ESI (m/z): [M+H]+ calcd. 
for C23H38N3O8: 484.2653, found, 484.2652.  
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3-Chloro-N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)benzamide boron-
fluoride complex adduct (2.6a) 
 
General Procedure B. To a solution of 3-Chloro-N-(1,3-dihydroxy-2-
(hydroxymethyl)propan-2-yl)benzamide (2.5a) (1.0mmol) in dichloromethane (DCM) (5 
mL) was added trimethyl borate (B(OMe)3) (1.0mmol) at room temperature under 
nitrogen. The reaction mixture was then heated to reflux for 5 hrs. The reaction mixture 
was then concentrated in vacuo to remove all the solvent. The resulting crude compound 
(Tris borate ester) was dried overnight under high vacuum, and directly used for the next 
step without further purification. Then Tris borate ester was dissolved in anhydrous 
ethanol (EtOH), and potassium fluoride (KF) (1.0 eqv.) was added, the resulting 
suspension was stirred at room temperature (RT) overnight. The reaction mixture was 
then concentrated in vacuo to remove all the solvent, the crude was then dried overnight 
under high vacuum to afford compound 2.6a (potassium salt of boron-fluoride complex 
adduct 2.6a) as a white solid in quantitative yield. 1HNMR (400MHz, D2O) ppm = 3.73 
(s, 6 H) 7.25 - 7.33 (m, 1 H) 7.42 (d, J=7.81 Hz, 1 H) 7.48 (d, J=7.42 Hz, 1 H) 7.58 (br. 
s., 1 H). 13CNMR (101MHz, D2O) ppm = 169.9, 135.9, 133.8, 131.7, 130.0, 127.1, 
125.5, 62.4, 60.2. 19FNMR (376MHz, D2O) ppm = -123.0. 11BNMR (160MHz, D2O) 
ppm = 16.3. HRMS-ESI (m/z): calcd. for C11H11[11B]FClNO4: 286.0459, found, 
286.0468.  
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(S)-benzyl (1-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-1-
oxopropan-2-yl)carbamate boron-fluoride complex adduct (2.6b) 
 
Compound 2.6b was prepared from compound 2.5b, trimethyl borate and 
potassium fluoride (KF) according to general procedure B to afford 2.6b as a white solid 
in quantitative yield. 1HNMR (400MHz, CD3OD)  ppm = 1.28 - 1.37 (m, 3 H), 3.57 - 
3.84 (m, 6 H), 4.14 (dq, J=14.21, 6.98 Hz, 1 H), 5.03 - 5.14 (m, 2 H), 7.22 - 7.42 (m, 5 
H). 13CNMR (101MHz, CD3OD)  ppm = 156.9, 136.6, 128.0, 127.6, 127.4, 127.3, 66.3, 
61.8, 60.7, 57.1, 32.7. 19FNMR (376MHz, CD3OD) ppm = -152.5. 11BNMR (160MHz, 
CD3OD) ppm = 2.4. HRMS-ESI (m/z): calcd. for C15H19[11B]FN2O6: 353.1326, 
found, 353.1329.  
 
(S)-benzyl (1-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-3-
methyl-1-oxobutan-2-yl)carbamate boron-fluoride complex adduct (2.6c) 
H
NCbz N
H
O O
O
O B
F
K
 
Compound 2.6c was prepared from compound 2.5c, trimethyl borate and 
potassium fluoride (KF) according to general procedure B to afford 2.6c as a white solid 
in quantitative yield. 1HNMR (400MHz, CD3OD)  ppm = 0.94 (dd, J=11.72, 7.03 Hz, 6 
H), 2.05 (dt, J=12.69, 6.54 Hz, 1 H), 3.61 - 3.81 (m, 6 H), 3.88 - 3.99 (m, 1 H), 5.03 - 
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5.12 (m, 2 H), 7.24 - 7.37 (m, 5 H). 13CNMR (101MHz, CD3OD)  ppm = 173.5, 157.3, 
136.7, 128.0, 127.6, 127.4, 66.3, 62.1, 60.9, 30.4, 16.9. 19FNMR (376MHz, CD3OD) 
ppm = -152.7. 11BNMR (160MHz, CD3OD) ppm = 2.7. HRMS-ESI (m/z): calcd. for 
C17H23[11B]FN2O6: 381.1639, found, 381.1643.  
 
(S)-benzyl (1-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-1-oxo-3-
phenylpropan-2-yl)carbamate boron-fluoride complex adduct (2.6d) 
 
Compound 2.6d was prepared from compound 2.5d, trimethyl borate and 
potassium fluoride (KF) according to general procedure B to afford 2.6d as a white solid 
in quantitative yield. 1HNMR (400MHz, CD3OD)  ppm = 2.86 (dd, J=13.47, 9.57 Hz, 1 
H), 3.05 - 3.19 (m, 1 H), 3.53 - 3.79 (m, 6 H), 4.29 - 4.44 (m, 1 H), 4.96 - 5.05 (m, 2 H), 
7.11 - 7.36 (m, 12 H). 13CNMR (101MHz, CD3OD)  ppm = 173.3, 156.9, 137.1, 136.7, 
136.6, 129.0, 128.9, 128.1, 128.0, 127.5, 127.2, 127.1, 66.1, 62.0, 60.7, 57.0, 37.5. 
19FNMR (376MHz, CD3OD) ppm = -152.4. 11BNMR (160MHz, CD3OD) ppm = 2.3. 
HRMS-ESI (m/z): calcd. for C21H23[11B]FN2O6: 429.1639, found, 429.1641.  
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(S)-benzyl (1-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-3-(1H-
indol-3-yl)-1-oxopropan-2-yl)carbamate boron-fluoride complex adduct (2.6e) 
 
Compound 2.6e was prepared from compound 2.5e, trimethyl borate and 
potassium fluoride (KF) according to general procedure B to afford 2.6e as a white solid 
in quantitative yield. 1HNMR (400MHz, CD3OD)  ppm = 3.01 - 3.15 (m, 1 H), 3.20 - 
3.26 (m, 1 H), 3.51 - 3.71 (m, 6 H), 4.36 - 4.49 (m, 1 H), 5.01 (br. s., 2 H), 6.94 - 7.01 (m, 
1 H), 7.03 - 7.12 (m, 3 H), 7.18 - 7.36 (m, 7 H), 7.51 - 7.63 (m, 1 H). 13CNMR (101MHz, 
CD3OD)  ppm = 163.7, 155.3, 136.8, 136.6, 128.1, 128.0, 127.7, 127.5, 127.3, 127.2, 
121.0, 120.9, 118.3, 110.8, 61.9, 60.7, 59.9, 56.6, 32.8. 19FNMR (376MHz, CD3OD) 
ppm = -152.3. 11BNMR (160MHz, CD3OD) ppm = 2.3. HRMS-ESI (m/z): calcd. for 
C23H24[11B]FN3O6: 468.1748, found, 468.1766.  
 
(S)-benzyl tert-butyl (6-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-
yl)amino)-6-oxohexane-1,5-diyl)dicarbamate boron-fluoride complex adduct (2.6f) 
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Compound 2.6f was prepared from compound 2.5f, trimethyl borate and 
potassium fluoride (KF) according to general procedure B to afford 2.6f as a white solid 
in quantitative yield. 1HNMR (400MHz, CD3OD)  ppm = 1.42 (s, 11 H) 1.49 (d, J=6.64 
Hz, 2 H) 1.54 - 1.82 (m, 2 H) 3.10 (t, J=6.64 Hz, 2 H), 3.52 (d, J=5.08 Hz, 1 H), 3.68-
3.74 (m, 6 H), 3.92 (d, J=3.91 Hz, 1 H), 5.04 (s, 2 H), 7.22 - 7.38 (m, 5 H). 13CNMR 
(101MHz, CD3OD)  ppm = 171.3, 156.9, 137.0, 128.0, 127.5, 127.4, 127.3, 79.4, 65.8, 
61.8, 60.7, 55.4, 39.9, 30.2, 29.0, 27.2, 22.7. 19FNMR (376MHz, CD3OD) ppm = -
152.7. 11BNMR (160MHz, CD3OD) ppm = 2.9. HRMS-ESI (m/z): calcd. for 
C23H34[11B]FN3O8: 510.2428, found, 510.2446.  
 
N1-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-N4-(2,4-
dimethoxybenzyl)succinamide (2.10a) 
 
General Procedure C. To a solution of 2,4-dimethoxybenzylamine (2.7a) (1.0 
mmol) in DMF (1mL) was added succinic anhydride (2.8) (1.0 mmol) at RT, the mixture 
was stirred at RT for 3hrs. Check TLC or LCMS to make sure the reaction was complete. 
Then another 1mL of DMF was added, followed by HCTU (1.3 mmol) and N,N-
Diisopropylethylamine (DIEA) (1.5 mmol) at RT under N2, the mixture was stirred for 
5mins. Then Tris (2.1) (1.5 mmol) was added in several portions, and the mixture was 
stirred at RT overnight. Once the reaction was completed, the reaction solution was 
concentrated to remove all the solvents, and resulting residue was extracted with hot ethyl 
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acetate (EtOAc), sequentially washed with sat. sodium bicarbonate solution, brine. Then 
the organic layer was dried over sodium sulfate (Na2SO4), concentrate to get crude 
product.  The resulting crude was then purified by flash column chromatography (silica 
gel, 100% EtOAc as eluent) to afford compound 2.10a as a white powder (41% yield). 
1HNMR (400MHz, D2O) ppm = 2.41 (dd, J=15.62, 5.86 Hz, 4 H), 3.53 - 3.62 (m, 6 H), 
3.70 (d, J=7.03 Hz, 6 H), 4.13 (s, 2 H) 6.41 - 6.47 (m, 1 H), 6.50 (d, J=2.34 Hz, 1 H), 
7.06 (d, J=8.20 Hz, 1 H). 13CNMR (101MHz, D2O) ppm = 175.1, 174.3, 159.8, 158.1, 
129.9, 118.5, 104.8, 98.7, 61.9, 60.4, 55.5, 55.4, 38.3, 31.5, 31.0. HRMS-ESI (m/z): 
[M+H]+ calcd. for C17H27N2O7: 371.1813, found, 371.1823.  
 
N1-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-N4-(4-
methoxybenzyl)succinamide (2.10b) 
 
Compound 2.10b was prepared from 4-methoxybenzylamine, succinic anhydride 
(2.8) and Tris (2.1) according to general procedure C to afford 2.10b as a white solid (35% 
yield). 1HNMR (400MHz, D2O) ppm = 2.36 - 2.57 (m, 4 H), 3.20 - 3.24 (m, 1 H), 3.59 
(s, 6 H), 3.70 (s, 3 H), 4.19 (s, 2 H), 6.83 - 6.90 (m, 2 H), 7.12 - 7.19 (m, 2 H). 13CNMR 
(101MHz, D2O) ppm = 175.1, 174.6, 158.0, 130.6, 128.7, 114.0, 61.9, 60.4, 55.3, 42.3, 
31.4, 31.0. HRMS-ESI (m/z): [M+H]+ calcd. for C16H25N2O6: 341.1707, found, 
341.1712.  
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N1-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-N4-(3,4-
dimethoxyphenethyl)succinamide (2.10c) 
 
Compound 2.10c was prepared from 2-(3,4-dimethoxyphenyl)ethanamine, 
succinic anhydride (2.8) and Tris (2.1) according to general procedure C to afford 2.10c 
as a white solid (56% yield). 1HNMR (400MHz, DMSO-d6)  ppm = 2.22 - 2.40 (m, 4 
H), 2.60 (t, J=7.22 Hz, 2 H), 3.21 (quin, J=6.54 Hz, 2 H), 3.39 (d, J=5.86 Hz, 3 H), 
3.50(s, 6H), 3.69 (s, 3 H), 3.72 (s, 3 H), 6.68 (d, J=7.81 Hz, 1 H), 6.77 (s, 1 H), 6.83 (d, 
J=8.20 Hz, 1 H), 7.89 (t, J=5.47 Hz, 1 H), 7.97 (br. s., 1 H). 13CNMR (101MHz, DMSO-
d6)  ppm = 173.4, 171.8, 149.0, 147.6, 132.4, 120.8, 112.9, 112.3, 62.7, 60.9, 55.9, 55.8, 
40.9, 35.1, 31.8, 31.3. HRMS-ESI (m/z): [M+H]+ calcd. for C18H29N2O7: 385.1969, 
found, 385.1972.  
 
N1-benzyl-N4-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)succinamide 
(2.10d) 
 
Compound 2.10d was prepared from benzylamine, succinic anhydride (2.8) and 
Tris (2.1) according to general procedure C to afford 2.10d as a white solid (68% yield).
1HNMR (400MHz, DMSO-d6)  ppm = 2.30 - 2.43 (m, 4 H), 3.50(s, 6H), 4.20 - 4.28 (m, 
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2 H), 4.64 (br. s., 3 H), 7.14 - 7.25 (m, 4 H), 7.25 - 7.33 (m, 2 H), 8.35 (t, J=5.86 Hz, 1 
H). 13CNMR (101MHz, DMSO-d6)  ppm = 173.3, 171.9, 139.9, 128.6, 127.5, 127.0, 
62.7, 60.9, 42.4, 31.8, 31.3. HRMS-ESI (m/z): [M+H]+ calcd. for C15H23N2O5: 
311.1601, found, 311.1585.  
 
Methyl 2-(4-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-4-
oxobutanamido)-3-(1H-indol-3-yl)propanoate (2.10e) 
H
N N
HO
O OH
OH
OH
MeO
O
HN
 
Compound 2.10e was prepared from H-Trp-OMe, succinic anhydride (2.8) and 
Tris (2.1) according to general procedure C to afford 2.10e as a white solid (36% yield).
1HNMR (400MHz, DMSO-d6)  ppm = 2.23 - 2.45 (m, 4 H), 2.95 - 3.17 (m, 2 H), 
3.38(br. s., 3H), 3.49 (s, 6 H), 3.54 (s, 3 H), 4.40 - 4.52 (m, 1 H), 6.93 - 7.00 (m, 1 H), 
7.05 (t, J=7.62 Hz, 1 H), 7.12 (s, 1 H), 7.32 (d, J=7.81 Hz, 1 H), 7.46 (d, J=7.81 Hz, 1 H), 
7.94 (br. s., 1 H), 8.28 - 8.40 (m, 1 H), 10.85 (d, J=6.25 Hz, 1 H). 13CNMR (101MHz, 
DMSO-d6)  ppm = 173.1, 172.3, 171.3, 136.5, 127.5, 124.1, 121.4, 118.8, 118.4, 111.9, 
109.9, 109.8, 62.7, 60.9, 60.0, 59.8, 53.7, 52.2, 31.8, 31.6, 29.8. HRMS-ESI (m/z): 
[M+H]+ calcd. for C20H28N3O7: 422.1922, found, 422.1928.  
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N1-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-N4-(2,4-
dimethoxybenzyl)succinamide boron-fluoride complex adduct (2.11a) 
 
Compound 2.11a was prepared from compound 2.10a, trimethyl borate and 
potassium fluoride (KF) according to general procedure B to afford 2.11a as a white solid 
in quantitative yield. 1HNMR (400MHz, CD3OD)  ppm = 2.47 - 2.58 (m, 4 H), 3.66 - 
3.73 (m, 6 H), 3.77 (d, J=18.75 Hz, 6 H), 4.25 (s, 2 H), 6.44 (d, J=8.59 Hz, 1 H), 6.49 (d, 
J=1.95 Hz, 1 H), 7.10 (d, J=8.20 Hz, 1 H). 13CNMR (101MHz, CD3OD)  ppm = 174.4, 
173.0, 160.5, 158.3, 129.1, 118.3, 103.8, 97.7, 62.2, 61.0, 54.4, 54.3, 37.7, 31.3, 31.2. 
19FNMR (376MHz, CD3OD) ppm = -153.0. 11BNMR (160MHz, CD3OD) ppm = 4.4. 
HRMS-ESI (m/z): calcd. for C17H23[11B]FN2O7: 397.1588, found, 397.1610.  
 
N1-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-N4-(4-
methoxybenzyl)succinamide boron-fluoride complex adduct (2.11b) 
 
Compound 2.11b was prepared from compound 2.10b, trimethyl borate and 
potassium fluoride (KF) according to general procedure B to afford 2.11b as a white solid 
in quantitative yield. 1HNMR (400MHz, CD3OD)  ppm = 2.46 - 2.59 (m, 4 H), 3.69 (s, 
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6 H), 3.74 (s, 3 H), 4.27 (s, 2 H), 6.84 (d, J=8.59 Hz, 2 H), 7.18 (d, J=8.59 Hz, 2 H). 
13CNMR (101MHz, CD3OD)  ppm = 174.1, 172.8, 158.5, 131.9, 128.9, 128.8, 128.7, 
114.0, 61.1, 58.0, 55.4, 41.9, 31.8, 26.4. 19FNMR (376MHz, CD3OD) ppm = -151.9. 
11BNMR (160MHz, CD3OD) ppm = 3.2. HRMS-ESI (m/z): calcd. for 
C16H21[11B]FN2O6: 367.1482, found, 367.1499.  
 
N1-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-N4-(3,4-
dimethoxyphenethyl)succinamide boron-fluoride complex adduct (2.11c) 
 
Compound 2.11c was prepared from compound 2.10c, trimethyl borate and 
potassium fluoride (KF) according to general procedure B to afford 2.11c as a white solid 
in quantitative yield. 1HNMR (400MHz, CD3OD)  ppm = 2.43 - 2.52 (m, 4 H), 2.71 (t, 
J=7.42 Hz, 2 H), 3.35 (t, J=7.42 Hz, 2 H), 3.52 (d, J=1.17 Hz, 1 H), 3.66 - 3.73 (m, 6 H), 
3.78 (s,  3 H), 3.81 (s,  3 H),  6.74 (dd, J=8.01, 1.37 Hz, 1 H), 6.81 - 6.88 (m, 2 H). 
13CNMR (101MHz, CD3OD)  ppm = 174.3, 173.1, 148.8, 147.4, 132.1, 120.7, 112.3, 
111.6, 62.2, 60.9, 55.1, 55.0, 40.7, 34.6, 31.3, 30.8. 19FNMR (376MHz, CD3OD) ppm = 
-151.2. 11BNMR (160MHz, CD3OD) ppm = 2.7. HRMS-ESI (m/z): calcd. for 
C18H25[11B]FN2O7: 411.1744, found, 411.1767. 
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N1-benzyl-N4-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)succinamide 
boron-fluoride complex adduct (2.11d) 
H
N N
HO
O O
O
O B
F
K
 
Compound 2.11d was prepared from compound 2.10d, trimethyl borate and 
potassium fluoride (KF) according to general procedure B to afford 2.11d as a white solid 
in quantitative yield. 1HNMR (400MHz, CD3OD)  ppm = 2.53 - 2.58 (m, 4 H), 3.52 (d, 
J=1.17 Hz, 1 H), 3.69 - 3.73 (m, 6 H) 4.34 (s, 2 H), 7.20 - 7.30 (m, 5 H). 13CNMR 
(101MHz, CD3OD)  ppm = 173.1, 171.3, 131.5, 128.0, 127.0, 126.6, 61.0, 57.9, 42.6, 
30.7, 30.3. 19FNMR (376MHz, CD3OD) ppm =     -151.6. 11BNMR (160MHz, CD3OD) 
ppm = 2.8. HRMS-ESI (m/z): calcd. for C15H19[11B]FN2O5: 337.1377, found, 
337.1386. 
 
Methyl 2-(4-((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-4-
oxobutanamido)-3-(1H-indol-3-yl)propanoate boron-fluoride complex adduct 
(2.11e) 
 
Compound 2.11e was prepared from compound 2.10e, trimethyl borate and 
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potassium fluoride (KF) according to general procedure B to afford 2.11e as a white solid 
in quantitative yield. 1HNMR (400MHz, CD3OD)  ppm = 2.44 - 2.51 (m, 4 H), 3.11 - 
3.25 (m, 2 H), 3.48 (s, 3 H), 3.63 - 3.68 (m, 6 H), 4.17 (s, 1 H), 4.69 (t, J=6.64 Hz, 1 H), 
6.95 - 7.02 (m, 1 H), 7.03 - 7.10 (m, 2 H), 7.32 (d, J=8.20 Hz, 1 H), 7.49 (d, J=7.81 Hz, 1 
H). 13CNMR (101MHz, CD3OD)  ppm = 174.2, 172.7, 169.1, 136.6, 127.2, 123.1, 
120.9, 118.3, 117.6, 110.9, 109.1, 75.6, 71.1, 64.0, 60.9, 53.6, 51.2, 30.8, 30.4, 27.0. 
19FNMR (376MHz, CD3OD) ppm = -151.5. 11BNMR (160MHz, CD3OD) ppm = 
2.83.  HRMS-ESI (m/z): calcd. for C20H24[11B]FN3O7: 448.1697, found, 448.1674. 
 
Ammonium salt of boron-fluoride complex adduct (2.14) 
 
General Procedure D. Preparation of Tris borate ester (2.13): to a solution of 
1,1,1-Tris(hydroxymethyl)ethane (2.12) (961.2 mg, 8.0mmol) in dichloromethane (DCM) 
(30 mL) was added trimethyl borate (B(OMe)3) (832 mg, 8.0 mmol) at room temperature 
under nitrogen. The reaction mixture was then heated to reflux for 3 hrs. The reaction 
mixture was then concentrated in vacuo to remove all the solvent. The resulting crude 
compound 2.13 (Tris borate ester) was dried overnight under high vacuum, and directly 
used for the next step without further purification.  
Preparation of Ammonium salt of boron-fluoride complex adduct(2.14): 1.0g of 
ion-exchange resin (Amberlite_IRA-67, free base) was loaded into a syringe column, 
then rinsed with 10mL of 2M HCl solution, then rinsed with 10mL of 2M potassium 
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fluoride (KF) solution for 3mins. Deionized water was added to remove excess KF 
solution, followed by rinses of 15mL of methanol, 10mL of anhydrous ethanol. After 
that, the solution of Tris borate ester (2.13) (50mg) in ethanol (2mL) was added to the 
resin and kept for 3mins. Once the reaction was complete, 10mL of 1N ammonium 
bicarbonate solution was added to elute the product as an ammonium salt solution. The 
collected ammonium solution was freeze-dried to afford the final product: Ammonium 
salt of boron-fluoride complex adduct as a white solid in 80% yield. 1HNMR (400MHz, 
D2O) ppm = 0.758 (3, 3H), 3.39 (s, 6 H). 13CNMR (101MHz, D2O) ppm = 64.4, 41.0, 
15.5. 19FNMR (376MHz, D2O) ppm = -143.5. 11BNMR (80.2MHz, D2O) ppm = 0.34. 
HRMS-ESI (m/z): calcd. for C5H9[11B]FO3: 147.0634, found, 147.0632.  
 
Ammonium salt of boron-fluoride complex adduct (2.17) 
 
General Procedure E. Preparation of Tris analog (2.15): To a solution of Tris 2.1 
(1.0 mmol) in DMF (1mL) was added succinic anhydride (2.8) (1.0 mmol) at RT, the 
mixture was stirred at RT for 3hrs. The reaction was monitored by TLC or LCMS to 
insure completion. The reaction was concentrated to remove all the solvent, and the 
resulting crude compound was directly used for the next step without further purification. 
Preparation of Ammonium salt of boron-fluoride complex adduct(2.17): 1.0g of ion-
exchange resin (Amberlite_IRA-67, free base) was loaded into a syringe column, then a 
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solution of Tris analog (2.15) (1.0mmol) in methanol (3mL) was added into resin for 
3mins and, rinsed with methanol (15mL), anhydrous ethanol (10mL). Next, trimethyl 
borate (3mL) was added and kept for 3mins. Once the reaction was complete, 10mL of 
anhydrous ethanol was added into resin to remove excess trimethyl borate. After that, a 
solution of potassium fluoride (KF) / 18-crown-6 in methanol was added and kept for 
3mins.  Once the reaction was complete, 10mL of 1N ammonium bicarbonate solution 
was added to elute the product as an ammonium salt solution. The collected ammonium 
solution was freeze-dried to afford the final product: Ammonium salt of boron-fluoride 
complex adduct as a white solid in 30% yield. 1HRMS-ESI (m/z): calcd. for 
C8H12[11B]FNO6: 248.0747, found, 248.0751.  
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